OPTH
Optimi Health Corp.
$4.55
+12.07%
$14.7M
No data for this timeframe.
Vol
Market Cap$14.7M
Cap SizeNano Cap
SEC Reports6
Press Releases1
Recent Activity
Jun 10, 2026
SEC
Optimi Health Corp. announced its first export of naturally derived psilocybin (biomass and 5mg capsules) to the UK to s
6-K — Impact 5/10
Jun 10, 2026
other
Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial
The shipment of naturally derived psilocybin, comprising both biomass and 5mg capsules, supports a p
Jun 8, 2026
SEC
Optimi Health Corp. announced it has secured naturally derived ibogaine from two sources and will commence finished drug
6-K — Impact 4/10
Jun 2, 2026
SEC
Optimi Health Corp. announced completion of a GMP production run of 5mg psilocybin capsules, the same formulation alread
6-K — Impact 4/10
May 29, 2026
Press
Optimi Health acknowledged the TGA's final recommendations expanding Australia's Authorized Prescriber scheme for psiloc
Impact 6/10
Latest Reports
BULLISH
6-K
5/10
Optimi Health Corp. announced its first export of naturally derived psilocybin (biomass and 5mg capsules) to the UK to s
Jun 10, 2026
NEUTRAL
6-K
4/10
Optimi Health Corp. announced it has secured naturally derived ibogaine from two sources and will commence finished drug
Jun 8, 2026
BULLISH
Press
6/10
Optimi Health acknowledged the TGA's final recommendations expanding Australia's Authorized Prescriber scheme for psiloc
May 29, 2026
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
6 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 2 mixed, 2 neutral. Avg impact: 5.2/10.
BULLISH
6-K
5/10
Optimi Health Corp. announced its first export of naturally derived psilocybin (biomass and 5mg caps
Jun 10, 2026
NEUTRAL
6-K
4/10
Optimi Health Corp. announced it has secured naturally derived ibogaine from two sources and will co
Jun 8, 2026
NEUTRAL
6-K
4/10
Optimi Health Corp. announced completion of a GMP production run of 5mg psilocybin capsules, the sam
Jun 2, 2026
BULLISH
6-K
6/10
Optimi Health Corp. acknowledged final TGA recommendations expanding the Authorized Prescriber schem
May 29, 2026
MIXED
F-1/A
6/10
Optimi Health Corp., a Canadian GMP-compliant manufacturer of psychedelic pharmaceuticals (MDMA and
Mar 24, 2026
MIXED
F-1/A
6/10
Optimi Health Corp., a Canadian psychedelic pharmaceutical manufacturer, is conducting an IPO to rai
Mar 13, 2026
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q 2026-09-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2026-09-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY 2027-09-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 82.7% | — |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 10, 2026
other
Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial
The shipment of naturally derived psilocybin, comprising both biomass and 5mg capsules, supports a planned Phase 2 clinical trial in the United Kingdo
Jun 2, 2026
announcement
Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia
<p align="center"><i>Optimi’s 5mg psilocybin capsules are prescribed commercially for treatment-resistant depression in Australia, with additional pro
May 29, 2026
announcement
Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia
<p align="center"><i>Updated TGA recommendations broaden therapist eligibility, accept a wider range of treatment settings, and reinforce Australia's